Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/185195
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSanz-Gómez, Marta-
dc.contributor.authorAledavood, Elnaz-
dc.contributor.authorBeroiz-Salaverri, Marina-
dc.contributor.authorLagartera, Laura-
dc.contributor.authorVega-Martín, Elena-
dc.contributor.authorGil-Ortega, Marta-
dc.contributor.authorCumella, José-
dc.contributor.authorPérez, Concepción-
dc.contributor.authorLuque Garriga, F. Xavier-
dc.contributor.authorEstarellas, Carolina-
dc.contributor.authorFernández-Alfonso, María S.-
dc.contributor.authorCastro, Ana-
dc.date.accessioned2022-04-28T10:10:19Z-
dc.date.available2022-04-28T10:10:19Z-
dc.date.issued2022-03-10-
dc.identifier.issn2045-2322-
dc.identifier.urihttp://hdl.handle.net/2445/185195-
dc.description.abstractEndothelial adenosine monophosphate-activated protein kinase (AMPK) plays a critical role in the regulation of vascular tone through stimulating nitric oxide (NO) release in endothelial cells. Since obesity leads to endothelial dysfunction and AMPK dysregulation, AMPK activation might be an important strategy to restore vascular function in cardiometabolic alterations. Here, we report the identification of a novel AMPK modulator, the indolic derivative IND6, which shows affinity for AMPKα1β1γ1, the primary AMPK isoform in human EA.Hy926 endothelial cells. IND6 shows inhibitory action of the enzymatic activity in vitro, but increases the levels of p-Thr174AMPK, p-Ser1177eNOS and p-Ser79ACC in EA.Hy926. This paradoxical finding might be explained by the ability of IND6 to act as a mixed-type inhibitor, but also to promote the enzyme activation by adopting two distinct binding modes at the ADaM site. Moreover, functional assays reveal that IND6 increased the eNOS-dependent production of NO and elicited a concentration-dependent vasodilation of endothelium-intact rat aorta due to AMPK and eNOS activation, demonstrating a functional activation of the AMPK-eNOS-NO endothelial pathway. This kinase inhibition profile, combined with the paradoxical AMPK activation in cells and arteries, suggests that these new chemical entities may constitute a valuable starting point for the development of new AMPK modulators with therapeutic potential for the treatment of vascular complications associated with obesity.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherNature Publishing Group-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-022-07077-8-
dc.relation.ispartofScientific Reports, 2022, vol. 12, p. 4225-
dc.relation.urihttps://doi.org/10.1038/s41598-022-07077-8-
dc.rightscc-by (c) Sanz-Gómez, Marta et al., 2022-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)-
dc.subject.classificationObesitat-
dc.subject.classificationInhibidors enzimàtics-
dc.subject.otherObesity-
dc.subject.otherEnzyme inhibitors-
dc.titleNovel indolic AMPK modulators induce vasodilatation through activation of the AMPK-eNOS-NO pathway-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec723015-
dc.date.updated2022-04-28T10:10:19Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)

Files in This Item:
File Description SizeFormat 
723015.pdf2.27 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons